Business Context and Reporting Period
Company: Oramed Pharmaceuticals Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: June 16, 2021
Principal Event: Entry into a new Material Definitive Agreement (Equity Distribution Agreement).
Key Financial Metrics and Capital Structure
This filing does not report standard operating financial metrics such as revenue, profit, cash flow, or margins. The financial data provided relates exclusively to a capital raising facility:
- New Offering Capacity: Up to $28,000,000 in aggregate offering price.
- Previous Facility Performance (Dec 1, 2020 – June 14, 2021): Sold 3,956,220 shares for gross proceeds of $38,548,161.
- Remaining Capacity (Old Facility): $1,451,839 available under the expiring 2020 Equity Distribution Agreement.
- Agent Commission: 3.0% of gross proceeds from sales under the new agreement.
Material Changes Versus Prior Period
The primary material change is the replacement of the Equity Distribution Agreement dated December 1, 2020, with a new agreement effective June 16, 2021. The new agreement increases the potential capital raise capacity by establishing a fresh $28,000,000 limit, separate from the remaining balance of the prior facility.
Guidance, Outlook, and Risks
Management Commentary and Outlook: The Company is not obligated to sell any shares under the new agreement. No assurance is given regarding the price, amount, or timing of any future sales. Sales will be conducted at the Company's discretion based on market conditions.
Risks and Contingencies:
- Termination: Either party may terminate the agreement with five days' notice; Canaccord Genuity may also terminate under certain specific circumstances.
- Market Risk: Sales are subject to market conditions and the Company's instructions regarding price and size limits.
- Regulatory: Sales are subject to the Company's effective shelf registration statement on Form S-3.
Key Facts for Investor Verification
- Verify the total dilution potential of the new $28,000,000 facility combined with the remaining $1,451,839 from the prior facility.
- Confirm the current share price to estimate the potential number of shares issuable under the new agreement.
- Review the full text of the Equity Distribution Agreement (Exhibit 1.1) for specific termination clauses and expense reimbursement details.
- Monitor future filings to track actual sales volume and proceeds generated under this new facility.